A grant from the Melanoma Research Foundation powers the initial stages of the project.
Study shows nearly 50% reduction in benign lesions excised.
New synthetic small molecule aims to counter drug resistance in BRAF-mutated melanomas.
Immunotherapy, intralesional treatments, multidisciplinary care teams define rapidly-evolving multimodal approach.
Data shows that the overall rate of melanoma diagnosis rose sixfold over the last 4 decades at a time when melanoma mortality stayed relatively stable.
The FDA has approved the fixed-dose combination of relatlimab plus nivolumab for the treatment of adult and pediatric patients who are 12 years of age or older and who have unresectable or metastatic melanoma.
A phase 1 study of davoceticept and pembrolizumab for advanced malignancies received a partial clinical hold from the FDA following a patient death.
The addition of bempegaldesleukin to nivolumab did not significantly improve progression-free survival, objective response rate, or overall survival vs nivolumab alone in the frontline treatment of patients with unresectable or metastatic melanoma, missing the primary end points of the phase 3 PIVOT IO-001 trial.
Researchers at the University of California in San Diego have discovered extrafollicular skin cells that transform into antimicrobial fat cells and fight acne, according to a study published in Science Translational Medicine.
The FDA has accepted an investigational new drug application for the photoimmunotherapy treatment, RM-1995, for patients with advanced cutaneous squamous cell carcinoma or head and neck squamous cell carcinoma.